Fingerprint
Dive into the research topics of 'Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Philip J. Mease, Atul A. Deodhar, Désirée Van Der Heijde, Frank Behrens, Alan J. Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee
Research output: Contribution to journal › Article › peer-review
86
Scopus
citations